Cargando…

Colorectal Transit and Volume During Treatment With Prolonged-release Oxycodone/Naloxone Versus Oxycodone Plus Macrogol 3350

BACKGROUND/AIMS: Opioid-induced constipation (OIC) is the most common gastrointestinal (GI) side effect to opioid treatment. Opioid receptor antagonists against OIC have been introduced, but their efficacy has not been directly compared to conventional laxatives. Our aim was to compare symptoms and...

Descripción completa

Detalles Bibliográficos
Autores principales:	Poulsen, Jakob L, Mark, Esben B, Brock, Christina, Frøkjær, Jens B, Krogh, Klaus, Drewes, Asbjørn M
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Korean Society of Neurogastroenterology and Motility 2018
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5753910/ https://www.ncbi.nlm.nih.gov/pubmed/29291613 http://dx.doi.org/10.5056/jnm17058

Ejemplares similares

Effects of Naloxegol on Gastrointestinal Transit and Colonic Fecal Volume in Healthy Participants Receiving Oxycodone
por: Olesen, Anne E, et al.
Publicado: (2019)

Pain therapy with oxycodone/naloxone prolonged-release combination: case report
por: Błaszczyk, Feliks, et al.
Publicado: (2013)

Intractable restless legs syndrome: role of prolonged-release oxycodone–naloxone
por: de Biase, Stefano, et al.
Publicado: (2016)

Methodological Issues on a Clinical Trial to Test Tapentadol Prolonged release vs. Oxycodone/Naloxone Prolonged release
por: Bacallao, Jorge, et al.
Publicado: (2016)

The place of oxycodone/naloxone in chronic pain management
por: Leppert, Wojciech
Publicado: (2013)

Opioid-Induced Bowel Dysfunction in Patients Undergoing Spine Surgery: Comparison of Oxycodone and Oxycodone-Naloxone Treatment
por: Kokki, Merja, et al.
Publicado: (2016)

A phase III randomized controlled study on the efficacy and improved bowel function of prolonged‐release (PR) oxycodone‐naloxone (up to 160/80 mg daily) vs oxycodone PR
por: Dupoiron, D., et al.
Publicado: (2017)

Efficacy and safety of controlled-release oxycodone/naloxone versus controlled-release oxycodone in Korean patients with cancer-related pain: a randomized controlled trial
por: Lee, Kyung-Hee, et al.
Publicado: (2017)

Developments in managing severe chronic pain: role of oxycodone–naloxone extended release
por: Fanelli, Guido, et al.
Publicado: (2015)

Long-term efficacy and safety of combined prolonged-release oxycodone and naloxone in the management of non-cancer chronic pain
por: Sandner-Kiesling, A, et al.
Publicado: (2010)

Efficacy and tolerability of low-dose oral prolonged-release oxycodone/naloxone for chronic nononcological pain in older patients
por: Guerriero, Fabio, et al.
Publicado: (2014)

Analgesic Efficacy and Safety of Prolonged-Release Oxycodone/Naloxone in Korean Patients with Chronic Pain from Spinal Disorders
por: Hwang, Chang Ju, et al.
Publicado: (2018)

Efficacy and tolerability of oral oxycodone and oxycodone/naloxone combination in opioid-naïve cancer patients: a propensity analysis
por: Lazzari, Marzia, et al.
Publicado: (2015)

Long-term safety and efficacy of oxycodone/naloxone prolonged-release tablets in patients with moderate-to-severe chronic cancer pain
por: Ahmedzai, Sam H., et al.
Publicado: (2014)

Quality of life under oxycodone/naloxone, oxycodone, or morphine treatment for chronic low back pain in routine clinical practice
por: Ueberall, Michael A, et al.
Publicado: (2016)

Treatment of Opioid Withdrawal Syndrome Triggered by Oxycodone/Naloxone with Dexmedetomidine
por: Go, Se-Il, et al.
Publicado: (2023)

Prolonged-Release (PR) Oxycodone/Naloxone Improves Bowel Function Compared with Oxycodone PR and Provides Effective Analgesia in Chinese Patients with Non-malignant Pain: A Randomized, Double-Blind Trial
por: Leng, Xiaomei, et al.
Publicado: (2020)

ENhANCE trial protocol: A multi-centre, randomised, phase IV trial comparing the efficacy of oxycodone/naloxone prolonged release (OXN PR) versus oxycodone prolonged release (Oxy PR) tablets in patients with advanced cancer
por: Wong, Aaron K., et al.
Publicado: (2022)

Cancer pain therapy with a fixed combination of prolonged-release oxycodone/naloxone: results from a non-interventional study
por: Nolte, Thomas, et al.
Publicado: (2013)

Hydrocortisone malabsorption due to polyethylene glycols (Macrogol 3350) in a girl with congenital adrenal insufficiency
por: Stagi, Stefano, et al.
Publicado: (2014)

Low-dose oral prolonged-release oxycodone/naloxone for chronic pain in elderly patients with cognitive impairment: an efficacy–tolerability pilot study
por: Petrò, Emiliano, et al.
Publicado: (2016)

Prolonged-release oxycodone/naloxone reduces opioid-induced constipation and improves quality of life in laxative-refractory patients: results of an observational study
por: Bantel, Carsten, et al.
Publicado: (2018)

Abuse Potential of Intravenous Oxycodone/Naloxone Solution in Nondependent Recreational Drug Users
por: Colucci, Salvatore V., et al.
Publicado: (2014)

Combined Administration of Oxycodone/Naloxone in Chronic Osteo-Articular Diseases Pain Therapy
por: Rosa, Palomba, et al.
Publicado: (2014)

Effects of an Oxycodone Conjugate Vaccine on Oxycodone Self-Administration and Oxycodone-Induced Brain Gene Expression in Rats
por: Pravetoni, Marco, et al.
Publicado: (2014)

Combatting pain after orthopedic/trauma surgery- perioperative oral extended-release tapentadol vs. extended-release oxycodone/naloxone
por: Haeseler, Gertrud, et al.
Publicado: (2017)

Oxycodone/Naloxone: Role in Chronic Pain Management, Opioid-Induced Constipation, and Abuse Deterrence
por: DePriest, Anne Z., et al.
Publicado: (2014)

Assessment of Neurotoxic Effects of Oxycodone and Naloxone in SH-SY5Y Cell Line
por: Lima, Luíza Siqueira, et al.
Publicado: (2023)

Oxycodone Controlled Release in Cancer Pain Management
por: Biancofiore, Giuseppe
Publicado: (2006)

Long-term evaluation of combined prolonged-release oxycodone and naloxone in patients with moderate-to-severe chronic pain: pooled analysis of extension phases of two Phase III trials
por: Blagden, M, et al.
Publicado: (2014)

Relative Oral Bioavailability of an Abuse-Deterrent, Immediate-Release Formulation of Oxycodone, Oxycodone ARIR in a Randomized Study
por: Webster, Lynn R., et al.
Publicado: (2019)

A comparison between the administration of oral prolonged-release oxycodone-naloxone and transdermal fentanyl in patients with moderate-to-severe cancer pain: a propensity score analysis
por: Roberto, A, et al.
Publicado: (2017)

Switching to low-dose oral prolonged-release oxycodone/naloxone from WHO-Step I drugs in elderly patients with chronic pain at high risk of early opioid discontinuation
por: Lazzari, Marzia, et al.
Publicado: (2016)

Profile of extended-release oxycodone/acetaminophen for acute pain
por: Bekhit, Mary Hanna
Publicado: (2015)

Relapsing thrombotic microangiopathy and intravenous sustained-release oxycodone
por: Nataatmadja, Melissa, et al.
Publicado: (2016)

Changes in oxycodone and heroin exposures in the National Poison Data System after introduction of extended-release oxycodone with abuse-deterrent characteristics
por: Coplan, Paul M, et al.
Publicado: (2013)

Oxycodone/naloxone as a therapeutic option in a patient with chronic pain and opioid-induced bowel dysfunction
por: Kraj, Leszek, et al.
Publicado: (2014)

Influence of tapentadol and oxycodone on the spinal cord and brain using electrophysiology: a randomized, placebo‐controlled trial
por: Nedergaard, Rasmus Bach, et al.
Publicado: (2022)

Use of Oxycodone in Pain Management
por: Moradi, Mohammad, et al.
Publicado: (2012)

Epidural Oxycodone for Acute Pain
por: Piirainen, Panu, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_6cbt6oelb6qs4jnek66ak9pku4